ANI Pharmaceuticals Inc (ANIP) 70.18 $ANIP
ANI Pharmaceuticals Schedules Conference Call for Second Quarter and Year-to-Date 2015 Financial Results
PR Newswire - Tue Jul 28, 7:00AM CDT
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its second quarter and year-to-date 2015 financial results on Tuesday, August 4, 2015, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com.
ANIP: 70.18 (-1.14)
ANI Pharmaceuticals wins US FDA approval of ANDA for Nimodipine 30mg Capsules
M2 - Tue Jul 28, 3:27AM CDT
Pharmaceutical company ANI Pharmaceuticals (NasdaqGM:ANIP) reported on Monday that its ANDA collaboration partner Sofgen has received approval from the US Food and Drug Administration (FDA) of the Abbreviated New Drug Application (ANDA) for Nimodipine 30mg Capsules.
ANIP: 70.18 (-1.14)
ANI Pharmaceuticals and Sofgen Announce FDA Approval of Nimodipine 30mg Capsules
PR Newswire - Mon Jul 27, 7:00AM CDT
ANI Pharmaceuticals, Inc. ("ANI"
(NASDAQ: ANIP) today announced that its ANDA collaboration partner Sofgen has received approval from the U.S. Food and Drug Administration (FDA) of the Abbreviated New Drug Application (ANDA) for Nimodipine 30mg Capsules. Trailing twelve-month sales for the product are $25 million, according to IMS Health, with two current competitors. ANI and Sofgen expect to begin shipping to customers this year.
ANIP: 70.18 (-1.14)
ANI Pharmaceuticals buys USD25m generic drug products
M2 - Tue Jul 14, 5:41AM CDT
Specialist pharmaceutical company ANI Pharmaceuticals (NasdaqGM:ANIP) revealed on Monday the completion of the acquisition of generic drug products for USD25m in cash.
ANIP: 70.18 (-1.14)
ANI Pharmaceuticals Acquires 22 Generic Drug Products from Teva Pharmaceuticals for $25 million
PR Newswire - Mon Jul 13, 7:00AM CDT
ANI Pharmaceuticals, Inc. ("ANI" (NASDAQ: ANIP) today announced that it has acquired 22 previously marketed generic drug products from Teva Pharmaceuticals for $25 million in cash and a percentage of future gross profits from product sales. The acquisition includes 19 solid-oral dosage products, and 3 oral suspension products. ANI will initially focus to tech transfer four products that qualify as CBE30 filings into ANI's two manufacturing facilities; these four products have a combined trailing twelve month market value of $210 million, according to IMS Health. The total market value for the 22 products is $650 million on a trailing twelve month basis, per IMS Health. The acquisition is being funded through cash on hand.
ANIP: 70.18 (-1.14)
Reflux Esophagitis (Gastroesophageal Reflux Disease) - API Insights 2015-2016
M2 - Fri Jul 10, 8:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q6zxdj/reflux) has announced the addition of the "Reflux Esophagitis (Gastroesophageal Reflux Disease)-API Insights" report to their offering. Reflux Esophagitis (Gastroesophageal Reflux Disease) - API Insights, 2015 report provides Reflux Esophagitis (Gastroesophageal Reflux Disease) drugs marketed details and API Manufacturers details across the globe along with the location. The report gives the clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the drugs falling under Reflux Esophagitis (Gastroesophageal Reflux Disease). The Report provides the India and China API Manufactures who are driving the current API Market. The report also highlights the patent, patent exclusivity information and competitive landscape. The research analysis also presents the global sales forecasts data for the Reflux Esophagitis (Gastroesophageal Reflux Disease) drugs till 2016. The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have strict guidelines for API manufacturing 'Process Validation: General Principles and Practices'. While countries such as Japan and Singapore are signatories to the ICH Q7 regulation, India and China follow their national GMP guidelines. The efficiency and expertise of Asian contract manufacturers have positioned them in a very strategic space in the global pharmaceutical supply chain, with a vast majority of the APIs and intermediates being sourced from markets such as India and China. Scope - A snapshot of the global Market therapeutics scenario for Renal Stones/Calculi. - A review of the marketed products under prescription for Renal Stones/Calculi, regulatory information and marketing status. - Coverage of global patent coverage and detailed commentaries on the US patent challenges. - Graphical representation of investigational products for patent expiry and market exclusivities across the globe. - Product profiles for marketed products for Renal Stones/Calculi with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details. - Coverage of API Manufacturers for Renal Stones/Calculi drugs in the United States, Europe and Asian Regions with location details. - Coverage of Regulatory filings in the US, Europe, and Asia specifically India and China for Renal Stones/Calculi drugs. - Key discontinued Marketed products. - Global Sales Figure from 2012-2016. Companies Mentioned - Salix Pharmaceuticals Ltd. - Santarus, Inc. - Covis Pharmaceuticals, Inc - GlaxoSmithKline Inc. - AstraZeneca PLC - Hanmi USA, Inc. - Braintree Laboratories, Inc. - SmithKline Beecham PLC - GlaxoSmithKline plc - AstraZeneca Pharmaceuticals, LP - Takeda Pharmaceuticals U.S.A., Inc. - UCB, Inc. - Pfizer Inc. - ANI Pharmaceuticals, Inc. - American Home Products Corporation - Alaven Pharmaceutical LLC (Inactive) - Teva Pharmaceutical Industries Limited - Merck & Co., Inc. - Eisai Inc. - Perrigo Company For more information visit http://www.researchandmarkets.com/research/q6zxdj/reflux
SNTS: (), PRGO: 193.24 (+1.17), ANIP: 70.18 (-1.14), PFE: 35.74 (+0.39), MRK: 58.74 (+1.22), AZN: 32.85 (+0.04), SLXP: 172.96 (+0.15), TEVA: 71.22 (-0.19), GSK: 42.85 (+1.14)
Contraception Pipeline Report 2015 - 12 Companies & 24 Drug Profiles
M2 - Fri Jul 10, 2:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nrq8z6/contraception) has announced the addition of the "Contraception - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Contraception, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Contraception and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Actavis plc - Agile Therapeutics, Inc. - ANI Pharmaceuticals, Inc. - Antares Pharma, Inc. - Evofem, Inc. - Hydra Biosciences, Inc. - Intas Pharmaceuticals Ltd. - Ligand Pharmaceuticals, Inc. - Merck & Co., Inc. - Orbis Biosciences, Inc. - Pantarhei Bioscience BV - Teva Pharmaceutical Industries Limited Drug Profiles - (ethinyl estradiol levonorgestrel) - (ethinylestradiol levonorgestrel) - (nestorone estradiol) - (prasterone estradiol progesterone) - AG-200 ER - AG-200 SP - Amphora - esterol - etonogestrel - EVE-106 - levonorgestrel - LJ-102 - MK-8342B - Monoclonal Antibody Conjugates for Contraception - norethindrone - S-003296 - S-0101255 - Small Molecule 1 for Fertility Control - Small Molecule 2 for Fertility Control - Small Molecule to Modulate Progesterone Receptor for Fertility Control - Small Molecules to Block CatSper1 Ion Channel for Contraception - Synthetic Peptides for Contraception - tanaproget - ulipristal acetate For more information visit http://www.researchandmarkets.com/research/nr...traception
ANIP: 70.18 (-1.14), MRK: 58.74 (+1.22), TEVA: 71.22 (-0.19), ATRS: 2.02 (-0.04)
Contraception Therapeutic Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - Wed Jul 08, 11:30AM CDT
The report "Contraception - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Contraception. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/contraceptio...eport.html .
ANIP: 70.18 (-1.14), MRK: 58.74 (+1.22), TEVA: 71.22 (-0.19), ATRS: 2.02 (-0.04)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jul 06, 4:38PM CDT
TVIX: 5.81 (-0.20), NFBK: 15.15 (-0.02), SFBS: 38.38 (-0.01), ANIP: 70.18 (-1.14), SHLM: 37.32 (+1.47), KTOS: 5.68 (+0.19), LONG: 13.49 (-0.16), COLM: 60.34 (+0.24)
New Strong Sell Stocks for July 2nd - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 02, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
ATEC: 1.37 (+0.01), ANIP: 70.18 (-1.14), BIP: 42.66 (+0.40), CBPX: 21.10 (+0.34), CLC: 58.71 (+0.86)
New Strong Sell Stocks for June 29th - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 29, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Monday
EARN: 14.02 (+0.03), CNW: 38.98 (+1.96), ANIP: 70.18 (-1.14), RDY: 58.65 (-1.04), DXPE: 37.17 (-0.02)
ANI Pharmaceuticals: The Rally Has Just Begun
Bret Jensen - at Seeking Alpha - Fri Jun 26, 1:53PM CDT
ANIP: 70.18 (-1.14)
Cancer Immunomodulators Market & Pipeline Insight 2020: with Bristol-Myers Squibb, MedImmune and AVAX Technologies Dominating
M2 - Tue Jun 16, 10:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t56mks/cancer) has announced the addition of the "Cancer Immunomodulators Market & Pipeline Insight 2020" report to their offering. Immune system has developed myriad of techniques for preventing progression and proliferation of infectious diseases in the body. Different immunocytes vary in qualitative/quantitative interaction with different components due to which variable immune reactions are produced. The intensity of these interactions could be modified with the help of immunomodulators. They could be natural occurring or synthetically derived molecule used for modulating activities of immune system. Immunomodulators have ability to augment or reduce immune reactions depending upon nature of ailment. In their presence, immune system produces those molecules which increase the rate of reaction and increases immunity. On the other hand, these molecules may reduce the effect of immune system in order to alleviate the patients' medical condition. Investigators have been able to identify their clinical applicability in various diseases due to which various immunomodulator based products are entering in global market. They are continuously changing due to which they may be tweaked according to medical necessity. Owing to multiple effects on immune system, sometimes they may be observed in overlapping drug categories. Immunomodulators present in body may undergo biochemical and biophysical changes and become overactive to target own components. Companies Mentioned: - 3M Pharmaceuticals - ANI Pharmaceuticals - AVAX Technologies - AbGenomics Corporation - Advaxis - Amgen - Argos Therapeutics - Baxter International - Biosidus - Biovest International - Celgene Corporation - Curadev - GlaxoSmithKline - Gradalis - Incyte - Intas Biopharmaceuticals - iTeos Therapeutics - Kyorin Pharmaceutical - Liponova - MedImmune - Merck - Mologen - NewLink Genetics Corporation - Northwest Biotherapeutics - Novartis - Peregrine Pharmaceuticals - Pfizer - Reliance Life Sciences - Roche - Sanofi - Toray - Vaccinogen For more information visit http://www.researchandmarkets.com/research/t56mks/cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ARGS: 6.22 (+0.02), NWBO: 11.65 (-0.35), BAX: 38.52 (+0.43), ANIP: 70.18 (-1.14), MRK: 58.75 (+1.23), NLNK: 51.13 (-2.68), AMGN: 171.89 (-0.85), GSK: 42.85 (+1.14), BMY: 64.50 (-0.16), NVS: 103.84 (+1.05), CELGZ: 2.06 (+0.02)
Failed Greece Negotiations Hit Futures; Dollar Worries Persist
at The Street - Mon Jun 15, 4:50AM CDT
But investors are likely to be wary ahead of the Fed meeting.
ACT: 298.98 (-2.94), HON: 105.73 (+1.53), FCX: 12.37 (+0.04), GRMN: 42.64 (-0.15), TM: 132.20 (+0.36), LVS: 54.63 (+0.49), ADBE: 80.44 (-0.15), DD: 56.10 (+0.20), AXTA: 30.28 (-0.06), AAPL: 122.76 (-0.62), FDX: 172.47 (+3.04), KR: 38.78 (+0.06), MCK: 226.40 (-0.34), ABX: 7.16 (+0.27), CS: 29.22 (+0.27), VEDL: 8.32 (+0.19), TIF: 94.64 (+2.65), CNSI: 19.85 (-0.14), ORCL: 39.53 (+0.25), DRI: 72.81 (+0.38), RAD: 8.90 (+0.15), NFLX: 107.33 (+0.43), WBA: 96.74 (+0.52), ANIP: 70.18 (-1.14), RHT: 78.80 (+0.07), CVS: 113.19 (+1.55), GM: 31.75 (+0.43), BABA: 80.68 (+0.12)
ANI Pharmaceuticals: Small Acquisitions Are Paying Off
Hillside Advisors - Seeking Alpha - Wed Jun 03, 4:26PM CDT
Overview ANI Pharmaceuticals (NASDAQ: ANIP ) is a small specialty pharmaceutical company with a line of branded and generic prescription products. The company is focused on pain (narcotics), anti-cancer (oncolytics), women's health (hormones and...
ANIP: 70.18 (-1.14)
ANI Pharmaceuticals wins US FDA approval of Oxycodone Hydrochloride Oral Solution 5mg/5ml for the management of pain
M2 - Wed Jun 03, 3:11AM CDT
Pharmaceutical company ANI Pharmaceuticals (NasdaqGM:ANIP) reported on Tuesday the receipt of approval from the US Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Oxycodone Hydrochloride Oral Solution 5mg/5ml in the area of pain management.
ANIP: 70.18 (-1.14)
ANI Pharmaceuticals Schedules Conference Call for Second Quarter and Year-to-Date 2015 Financial Results
PR Newswire - Tue Jul 28, 7:00AM CDT
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its second quarter and year-to-date 2015 financial results on Tuesday, August 4, 2015, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com.
ANIP: 70.18 (-1.14)
ANI Pharmaceuticals wins US FDA approval of ANDA for Nimodipine 30mg Capsules
M2 - Tue Jul 28, 3:27AM CDT
Pharmaceutical company ANI Pharmaceuticals (NasdaqGM:ANIP) reported on Monday that its ANDA collaboration partner Sofgen has received approval from the US Food and Drug Administration (FDA) of the Abbreviated New Drug Application (ANDA) for Nimodipine 30mg Capsules.
ANIP: 70.18 (-1.14)
ANI Pharmaceuticals and Sofgen Announce FDA Approval of Nimodipine 30mg Capsules
PR Newswire - Mon Jul 27, 7:00AM CDT
ANI Pharmaceuticals, Inc. ("ANI"
(NASDAQ: ANIP) today announced that its ANDA collaboration partner Sofgen has received approval from the U.S. Food and Drug Administration (FDA) of the Abbreviated New Drug Application (ANDA) for Nimodipine 30mg Capsules. Trailing twelve-month sales for the product are $25 million, according to IMS Health, with two current competitors. ANI and Sofgen expect to begin shipping to customers this year. ANIP: 70.18 (-1.14)
ANI Pharmaceuticals buys USD25m generic drug products
M2 - Tue Jul 14, 5:41AM CDT
Specialist pharmaceutical company ANI Pharmaceuticals (NasdaqGM:ANIP) revealed on Monday the completion of the acquisition of generic drug products for USD25m in cash.
ANIP: 70.18 (-1.14)
ANI Pharmaceuticals Acquires 22 Generic Drug Products from Teva Pharmaceuticals for $25 million
PR Newswire - Mon Jul 13, 7:00AM CDT
ANI Pharmaceuticals, Inc. ("ANI"
(NASDAQ: ANIP) today announced that it has acquired 22 previously marketed generic drug products from Teva Pharmaceuticals for $25 million in cash and a percentage of future gross profits from product sales. The acquisition includes 19 solid-oral dosage products, and 3 oral suspension products. ANI will initially focus to tech transfer four products that qualify as CBE30 filings into ANI's two manufacturing facilities; these four products have a combined trailing twelve month market value of $210 million, according to IMS Health. The total market value for the 22 products is $650 million on a trailing twelve month basis, per IMS Health. The acquisition is being funded through cash on hand. ANIP: 70.18 (-1.14)
Reflux Esophagitis (Gastroesophageal Reflux Disease) - API Insights 2015-2016
M2 - Fri Jul 10, 8:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q6zxdj/reflux) has announced the addition of the "Reflux Esophagitis (Gastroesophageal Reflux Disease)-API Insights" report to their offering. Reflux Esophagitis (Gastroesophageal Reflux Disease) - API Insights, 2015 report provides Reflux Esophagitis (Gastroesophageal Reflux Disease) drugs marketed details and API Manufacturers details across the globe along with the location. The report gives the clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the drugs falling under Reflux Esophagitis (Gastroesophageal Reflux Disease). The Report provides the India and China API Manufactures who are driving the current API Market. The report also highlights the patent, patent exclusivity information and competitive landscape. The research analysis also presents the global sales forecasts data for the Reflux Esophagitis (Gastroesophageal Reflux Disease) drugs till 2016. The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have strict guidelines for API manufacturing 'Process Validation: General Principles and Practices'. While countries such as Japan and Singapore are signatories to the ICH Q7 regulation, India and China follow their national GMP guidelines. The efficiency and expertise of Asian contract manufacturers have positioned them in a very strategic space in the global pharmaceutical supply chain, with a vast majority of the APIs and intermediates being sourced from markets such as India and China. Scope - A snapshot of the global Market therapeutics scenario for Renal Stones/Calculi. - A review of the marketed products under prescription for Renal Stones/Calculi, regulatory information and marketing status. - Coverage of global patent coverage and detailed commentaries on the US patent challenges. - Graphical representation of investigational products for patent expiry and market exclusivities across the globe. - Product profiles for marketed products for Renal Stones/Calculi with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details. - Coverage of API Manufacturers for Renal Stones/Calculi drugs in the United States, Europe and Asian Regions with location details. - Coverage of Regulatory filings in the US, Europe, and Asia specifically India and China for Renal Stones/Calculi drugs. - Key discontinued Marketed products. - Global Sales Figure from 2012-2016. Companies Mentioned - Salix Pharmaceuticals Ltd. - Santarus, Inc. - Covis Pharmaceuticals, Inc - GlaxoSmithKline Inc. - AstraZeneca PLC - Hanmi USA, Inc. - Braintree Laboratories, Inc. - SmithKline Beecham PLC - GlaxoSmithKline plc - AstraZeneca Pharmaceuticals, LP - Takeda Pharmaceuticals U.S.A., Inc. - UCB, Inc. - Pfizer Inc. - ANI Pharmaceuticals, Inc. - American Home Products Corporation - Alaven Pharmaceutical LLC (Inactive) - Teva Pharmaceutical Industries Limited - Merck & Co., Inc. - Eisai Inc. - Perrigo Company For more information visit http://www.researchandmarkets.com/research/q6zxdj/reflux
SNTS: (), PRGO: 193.24 (+1.17), ANIP: 70.18 (-1.14), PFE: 35.74 (+0.39), MRK: 58.74 (+1.22), AZN: 32.85 (+0.04), SLXP: 172.96 (+0.15), TEVA: 71.22 (-0.19), GSK: 42.85 (+1.14)
Contraception Pipeline Report 2015 - 12 Companies & 24 Drug Profiles
M2 - Fri Jul 10, 2:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nrq8z6/contraception) has announced the addition of the "Contraception - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Contraception, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Contraception and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Actavis plc - Agile Therapeutics, Inc. - ANI Pharmaceuticals, Inc. - Antares Pharma, Inc. - Evofem, Inc. - Hydra Biosciences, Inc. - Intas Pharmaceuticals Ltd. - Ligand Pharmaceuticals, Inc. - Merck & Co., Inc. - Orbis Biosciences, Inc. - Pantarhei Bioscience BV - Teva Pharmaceutical Industries Limited Drug Profiles - (ethinyl estradiol levonorgestrel) - (ethinylestradiol levonorgestrel) - (nestorone estradiol) - (prasterone estradiol progesterone) - AG-200 ER - AG-200 SP - Amphora - esterol - etonogestrel - EVE-106 - levonorgestrel - LJ-102 - MK-8342B - Monoclonal Antibody Conjugates for Contraception - norethindrone - S-003296 - S-0101255 - Small Molecule 1 for Fertility Control - Small Molecule 2 for Fertility Control - Small Molecule to Modulate Progesterone Receptor for Fertility Control - Small Molecules to Block CatSper1 Ion Channel for Contraception - Synthetic Peptides for Contraception - tanaproget - ulipristal acetate For more information visit http://www.researchandmarkets.com/research/nr...traception
ANIP: 70.18 (-1.14), MRK: 58.74 (+1.22), TEVA: 71.22 (-0.19), ATRS: 2.02 (-0.04)
Contraception Therapeutic Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - Wed Jul 08, 11:30AM CDT
The report "Contraception - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Contraception. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/contraceptio...eport.html .
ANIP: 70.18 (-1.14), MRK: 58.74 (+1.22), TEVA: 71.22 (-0.19), ATRS: 2.02 (-0.04)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jul 06, 4:38PM CDT
TVIX: 5.81 (-0.20), NFBK: 15.15 (-0.02), SFBS: 38.38 (-0.01), ANIP: 70.18 (-1.14), SHLM: 37.32 (+1.47), KTOS: 5.68 (+0.19), LONG: 13.49 (-0.16), COLM: 60.34 (+0.24)
New Strong Sell Stocks for July 2nd - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 02, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
ATEC: 1.37 (+0.01), ANIP: 70.18 (-1.14), BIP: 42.66 (+0.40), CBPX: 21.10 (+0.34), CLC: 58.71 (+0.86)
New Strong Sell Stocks for June 29th - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 29, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Monday
EARN: 14.02 (+0.03), CNW: 38.98 (+1.96), ANIP: 70.18 (-1.14), RDY: 58.65 (-1.04), DXPE: 37.17 (-0.02)
ANI Pharmaceuticals: The Rally Has Just Begun
Bret Jensen - at Seeking Alpha - Fri Jun 26, 1:53PM CDT
ANIP: 70.18 (-1.14)
Cancer Immunomodulators Market & Pipeline Insight 2020: with Bristol-Myers Squibb, MedImmune and AVAX Technologies Dominating
M2 - Tue Jun 16, 10:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t56mks/cancer) has announced the addition of the "Cancer Immunomodulators Market & Pipeline Insight 2020" report to their offering. Immune system has developed myriad of techniques for preventing progression and proliferation of infectious diseases in the body. Different immunocytes vary in qualitative/quantitative interaction with different components due to which variable immune reactions are produced. The intensity of these interactions could be modified with the help of immunomodulators. They could be natural occurring or synthetically derived molecule used for modulating activities of immune system. Immunomodulators have ability to augment or reduce immune reactions depending upon nature of ailment. In their presence, immune system produces those molecules which increase the rate of reaction and increases immunity. On the other hand, these molecules may reduce the effect of immune system in order to alleviate the patients' medical condition. Investigators have been able to identify their clinical applicability in various diseases due to which various immunomodulator based products are entering in global market. They are continuously changing due to which they may be tweaked according to medical necessity. Owing to multiple effects on immune system, sometimes they may be observed in overlapping drug categories. Immunomodulators present in body may undergo biochemical and biophysical changes and become overactive to target own components. Companies Mentioned: - 3M Pharmaceuticals - ANI Pharmaceuticals - AVAX Technologies - AbGenomics Corporation - Advaxis - Amgen - Argos Therapeutics - Baxter International - Biosidus - Biovest International - Celgene Corporation - Curadev - GlaxoSmithKline - Gradalis - Incyte - Intas Biopharmaceuticals - iTeos Therapeutics - Kyorin Pharmaceutical - Liponova - MedImmune - Merck - Mologen - NewLink Genetics Corporation - Northwest Biotherapeutics - Novartis - Peregrine Pharmaceuticals - Pfizer - Reliance Life Sciences - Roche - Sanofi - Toray - Vaccinogen For more information visit http://www.researchandmarkets.com/research/t56mks/cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ARGS: 6.22 (+0.02), NWBO: 11.65 (-0.35), BAX: 38.52 (+0.43), ANIP: 70.18 (-1.14), MRK: 58.75 (+1.23), NLNK: 51.13 (-2.68), AMGN: 171.89 (-0.85), GSK: 42.85 (+1.14), BMY: 64.50 (-0.16), NVS: 103.84 (+1.05), CELGZ: 2.06 (+0.02)
Failed Greece Negotiations Hit Futures; Dollar Worries Persist
at The Street - Mon Jun 15, 4:50AM CDT
But investors are likely to be wary ahead of the Fed meeting.
ACT: 298.98 (-2.94), HON: 105.73 (+1.53), FCX: 12.37 (+0.04), GRMN: 42.64 (-0.15), TM: 132.20 (+0.36), LVS: 54.63 (+0.49), ADBE: 80.44 (-0.15), DD: 56.10 (+0.20), AXTA: 30.28 (-0.06), AAPL: 122.76 (-0.62), FDX: 172.47 (+3.04), KR: 38.78 (+0.06), MCK: 226.40 (-0.34), ABX: 7.16 (+0.27), CS: 29.22 (+0.27), VEDL: 8.32 (+0.19), TIF: 94.64 (+2.65), CNSI: 19.85 (-0.14), ORCL: 39.53 (+0.25), DRI: 72.81 (+0.38), RAD: 8.90 (+0.15), NFLX: 107.33 (+0.43), WBA: 96.74 (+0.52), ANIP: 70.18 (-1.14), RHT: 78.80 (+0.07), CVS: 113.19 (+1.55), GM: 31.75 (+0.43), BABA: 80.68 (+0.12)
ANI Pharmaceuticals: Small Acquisitions Are Paying Off
Hillside Advisors - Seeking Alpha - Wed Jun 03, 4:26PM CDT
Overview ANI Pharmaceuticals (NASDAQ: ANIP ) is a small specialty pharmaceutical company with a line of branded and generic prescription products. The company is focused on pain (narcotics), anti-cancer (oncolytics), women's health (hormones and...
ANIP: 70.18 (-1.14)
ANI Pharmaceuticals wins US FDA approval of Oxycodone Hydrochloride Oral Solution 5mg/5ml for the management of pain
M2 - Wed Jun 03, 3:11AM CDT
Pharmaceutical company ANI Pharmaceuticals (NasdaqGM:ANIP) reported on Tuesday the receipt of approval from the US Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Oxycodone Hydrochloride Oral Solution 5mg/5ml in the area of pain management.
ANIP: 70.18 (-1.14)
